Abstract：
Multiple myeloma (MM) significantly increases the risk of venous thromboembolism (VTE) within 6 months of treatment initiation. The IMPEDE VTE score is a VTE risk prediction model which is recently incorporated into the National Comprehensive Cancer Network (NCCN) guidelines, but it lacks validation among Asians, including Chinese MM patients. We performed a retrospective chart review of 405 Chinese with newly diagnosed MM who started therapy at Beijing Jishuitan Hospital between April 2013 to October 2022. The 6-month cumulative incidence of VTE was 3.8 % (95 % CI:1.6-7.6), 8.6 % (95 % CI: 5.3-21.9) and 40.5 % (95 % CI: 24.9-55.7) in the low-, intermediate- and high-risk groups (P < 0.001), respectively. The C-statistic of the IMPEDE VTE scores for predicting VTE within 6 months of treatment initiation was 0.74 (95 % CI: 0.65-0.83). Of note, in this single-center cohort study, we propose that the anticoagulant LMWH may be more effective than the antiplatelet aspirin in potentially preventing VTE in newly diagnosed MM patients. Our findings suggest that the IMPEDE VTE score is a valid evidence-based risk stratification tool in Chinese patients with newly diagnosed MM.
摘要：
多发性骨髓瘤（MM）在治疗开始后6个月内显着增加了静脉血栓栓塞（VTE）的风险。IMPEDEVTE评分是一种VTE风险预测模型，最近被纳入国家综合癌症网络（NCCN）指南。但它缺乏亚洲人的验证，包括中国MM患者。我们对2013年4月至2022年10月在北京积水潭医院开始治疗的405例中国新诊断MM进行了回顾性图表回顾。VTE的6个月累积发生率为3.8％（95％CI：1.6-7.6），8.6%(95%CI:5.3-21.9)和40.5%(95%CI:24.9-55.7)，中危和高危人群(P<0.001)，分别。在治疗开始后6个月内预测VTE的IMPEDEVTE评分的C统计量为0.74（95％CI：0.65-0.83）。值得注意的是，在这项单中心队列研究中，我们认为,在新诊断的MM患者中,抗凝LMWH可能比抗血小板阿司匹林更有效地预防VTE.我们的研究结果表明，IMPEDEVTE评分是中国新诊断MM患者的有效的基于证据的风险分层工具。
